TP53 and acute myeloid leukemia: Our findings of the differential benefit of VEN addition to HMA by molecular ontogeny are supported by two recent risk models suggested for patients with AML treated with HMA + VEN, both included TP53 as an adverse risk prognostic marker and secondary ontogeny was not considered adverse risk in either [24–26].